Shionogi inks new hearing loss research deal with Cilcare

12 May 2025

Japanese drugmaker Shionogi (TYO: 4507) has entered into a joint research agreement with French firm Cilcare for the creation of a new drug pipeline for hearing loss.

The partnership builds on a previous 400 million-euro ($450 million) option agreement last year for Cilcare's hearing loss candidates CIL001 and CIL003, with Phase IIa studies for CIL001 planned to begin in fiscal year 2025.

Cilcare is one of the world's leading companies coupling advanced non-clinical research technology with clinical know-how, and, in an option agreement with Shionogi, is advancing the development of drug candidates for hearing loss (CIL001, CIL003).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK